Koesten, Hirschmann & Crabtree, Inc. Vertex Pharmaceuticals Inc Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $172 Billion
- Q3 2024
Number of Shares
0Holding current value
$0% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding VRTX
# of Institutions
1,725Shares Held
221MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$11 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$9.54 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.78 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.87 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$3.71 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $106B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...